Update on pharmacological strategies for stroke: Prevention, acute intervention and regeneration

Current Opinion in Investigational Drugs

Volumn 4, Issue 7, 2003, Pages 847-858

  Legos, Jeffrey J ^a   Barone, Frank C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Cerebral ischemia; Focal stroke; Neuroprotection; Prevention; Regeneration; Therapeutic window; Treatment

Indexed keywords

27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; 4 (4 FLUOROPHENYL) 2 METHYL 6 (5 PIPERIDINOPENTYLOXY)PYRIMIDINE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARUNDIC ACID; ATORVASTATIN; AX 200; AX 201; BAY 38 7271; BAY 44 2041; BB 10153; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BGC 728; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DELUCEMINE; DEXANABINOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISUFENTON SODIUM; DIURETIC AGENT; DROTRECOGIN; DVD 111; DY 9760E; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLUTAMATE RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTACYSTIN BETA LACTONE; MLN 01; MONTEPLASE; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NS 1209; NV 04; ODIPARCIL; OMEGA CONOTOXIN MVIIA; PROLYSE; REMACEMIDE; SARUPLASE; SGS 111; SIPATRIGINE; SN 429; SODIUM CHANNEL BLOCKING AGENT; SR 374; SUN N 4057; TAPGEN; THROMBIN INHIBITOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN; YM 337;

ANGIOPLASTY; ANTICOAGULANT THERAPY; BLEEDING; BRAIN DEVELOPMENT; BRAIN HEMORRHAGE; BRAIN INJURY; CELL DAMAGE; CELL LOSS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; CONVALESCENCE; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ENDARTERECTOMY; EVIDENCE BASED MEDICINE; EXPERIMENTATION; FIBRINOLYTIC THERAPY; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROPHYLAXIS; REVIEW; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ANIMALS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; NERVE REGENERATION; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; RECOVERY OF FUNCTION;

EID: 0142031072     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Fisher M, Bogousslavavsky J: Further evolution toward effective therapy for acute ischemic stroke. J Am Med Assoc (1998) 279(16):1298-1303.
2. Stephenson J: Rising stroke rates spur efforts to identify risks, prevent disease. J Am Med Assoc (1998) 279(16):1239-1240.
3. Feigin VL, Lawes CMM, Bennett DA, Anderson CS: Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol (2003) 2(1):43-53. An up-to-date overview of population-based studies of incidence, prevalence, mortality and case-fatality in stroke patients.
4. Pancioli AM, Borderick J, Kothari R, Brott T, Tuchfarber A, Miller R, Khoury J, Jauch E: Public perception of stroke warning signs and knowledge of potential risk factors. J Am Med Assoc (1998) 279(16):1288-1292.
5. Donnan GA, Davis SM: Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol (2002) 1(7):417-425.
6. Parsons AA, Irving EA, Legos JJ, Lenhard SC, Chandra S, Schaeffer TR, Haimbach RE, White RF, Hunter AJ, Barone FC: Acute stroke therapy: Translating preclinical neuroprotection to therapeutic reality. Curr Opin Invest Drugs (2000) 1(4):452-463. This review addresses the key issues in transferring preclinical data from animal models to a therapeutic setting.
7. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet (1997) 349(9065):1569-1581.
8. Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani MA, Lucas C, Bordet R: Stroke prevention - Management of modifiable vascular risk factors. J Neurol (2002) 249(5):507-517.
9. Hart RG, Bailey RD: An assessment of guidelines for prevention of ischemic stroke. Neurology (2002) 59(7):977-982.
10. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci (1996) 143(1-2):1-13.
11. Johnson E, Lanes SF, Wentworth CE 3rd, Satterfield MH, Abebe BL, Dicker LW: A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med (1999) 159(11):1248-1253.
12. Willard NR, Mach F: Statins: The new aspirin? Cell Mol Life Sci (2002) 59(11):1771-1786. A detailed review of the use of statins as a preventative therapy and the lipid-independent mechanisms by which they may exert their beneficial effects.
13. Lees KR: Management of acute stroke. Lancet Neurol (2002) 1(1):41-50.
14. Leker RR, Shohami E: Cerebral ischemia and trauma - Different etiologies yet similar mechanisms: Neuroprotective opportunities. Brain Res - Brain Research Rev (2002) 39(1):55-73.
15. Legos JJ, Tuma RF, Barone FC: Pharmacological interventions for stroke: Failures and future. Expert Opin Investig Drugs (2002) 11(5):603-614.
16. Frijns CJM, Kappelle LJ: Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke (2002) 33(8):2115-2122.
17. Emsley HCA, Tyrrell PJ: Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab (2002) 22(12):1399-1419.
18. Read SJ, Parsons AA, Harrison DC, Philpott K, Kabnick K, O'Brien S, Clark S, Brawner M, Bates S, Gloger I, Legos JJ et al.: Stroke genomics: Approaches to identify, validate, and understand ischemic stroke gene expression. J Cereb Blood Flow Metab (2001) 21(7):755-778. A review which outlines subsequent steps necessary for identification and validation of novel genes found using microarray technology.
19. Carr FJ, McBride MW, Carswell HVO, Graham D, Strahorn P, Clark JS, Charchar FJ, Dominiczak AF: Genetic aspects of stroke: Human and experimental studies. J Cereb Blood Flow Metab (2002) 22(7):767-773.
20. Barone FC, Parsons AA: Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opin Investig Drugs (2000) 9(10):2281-2306. This review summarizes the pathophysiology of stroke and emphasizes the potential of novel anti-inflammatory targets in stroke.
21. Wu O, Koroshetz WJ, Ostergaard L, Buonanno FS, Copen WA, Gonzalez RG, Rordorf G, Rosen BR, Schwamm LH, Weisskoff RM, Sorensen AG: Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. Stroke (2001) 32(4):933-942. Study suggesting the advantages of using combined diffusion and perfusion weighted MRI as an early diagnostic tool in stroke patients.
22. Thijs VN, Lansberg MG, Beaulieu C, Marks MP, Moseley ME, Albers GW: Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? A multivariable analysis. Stroke (2000) 31(11):2597-2602.
23. Oliveira-Filho J, Koroshetz WJ: Magnetic resonance imaging in acute stroke: Clinical perspective. Top Magn Reson Imaging (2000) 11(5):246-258.
24. Neumann-Haefelin T, Wittsack HJ, Wenserski F, Siebler M, Seitz RJ, Modder U, Freund HJ: Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. Stroke (1999) 30(8):1591-1597.
25. Nakayama Y, Ueno Y, Tanaka A, Nomoto Y, Takano K: Diagnostic value of perfusion MRI in classifying stroke. Keio J Med (2000) 49(Suppl 1):A51-A54.
26. Albers GW: Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke (1999) 30(10):2230-2237. First clinical study to demonstrate the potential utility of MRI to stratify patient populations prior to treatment.
27. Albers GW, Lansberg MG, Norbash AM, Tong DC, O'Brien MW, Woolfenden AR, Marks MP, Moseley ME: Yield of diffusion-weighted MRI for detection of potentially relevant findings in stroke patients. Neurology (2000) 54(8):1562-1567.
28. Chaves CJ, Silver B, Schlaug G, Dashe J, Caplan LR, Warach S: Diffusion- and perfusion-weighted MRI patterns in borderzone infarcts. Stroke (2000) 31(5):1090-1096.
29. Jacobs MA, Mitsias P, Soltanian-Zadeh H, Santhakumar S, Ghanei A, Hammond R, Peck DJ, Chopp M, Patel S: Multiparametric MRI tissue characterization in clinical stroke with correlation to clinical outcome: Part 2. Stroke (2001) 32(4):950-957.
30. Muir KW, Holzapfel L, Lees KR: Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc Dis (2000) 10(6):431-436.
31. Muir KW, Hamilton SJC, Lunnon MW, Hobbiger S, Lees KR: Safety and tolerability of 619c89 after acute stroke. Cerebrovasc Dis (1998) 8(1):31-37.
32. Hussein Z, Fraser IJ, Lees KR, Muir KW, Lunnon MW, Hobbiger SF, Posner J: Pharmacokinetics of 619c89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. Br J Clin Pharmacol (1996) 41(6):505-511.
33. Barone FC, Feuerstein GZ, Spera PA: Calcium channel blockers in cerebral ischemia. Expert Opin Investig Drugs (1997) 6:501-519.
34. Horn J, De Haan RJ, Vermeulen M, Limburg M: Very early nimodipine use in stroke (VENUS) - A randomized, double-blind, placebo-controlled trial. Stroke (2001) 32(2):461-465.
35. Horn J, De Haan RJ, Vermeulen M, Luiten PGM, Limburg M: Nimodipine in animal model experiments of focal cerebral ischemia - A systematic review. Stroke (2001) 32(10):2433-2438.
36. Horn J, Limburg M: Calcium antagonists for ischemic stroke: A systematic review. Stroke (2001) 32(2):570-576.
37. 2+ channel antagonists and neuroprotection from cerebral ischemia. Eur J Pharmacol (1998) 363(1):1-15.
38. Sauter A, Rudin M: Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke (1986) 17(6):1228-1234.
39. Koroshetz WJ, Moskowitz MA: Emerging treatments for stroke in humans. Trends Pharmacol Sci (1996) 17(6):227-233.
40. Siesjo BK: Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J Neurosurg (1992) 77(3):337-354.
41. 2+-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab (1994) 14(6):903-910.
42. Yenari MA, Palmer JT, Sun GH, De Crespigny A, Mosely ME, Steinberg GK: Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI. Brain Res (1996) 739(1-2):36-45.
43. Perezpinzon MA, Yenari MA, Sun GH, Kunis DM, Steinberg GK: SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J Neurol Sci (1997) 153(1):25-31.
44. Takahashi M, Ni JW, Kawasaki-Yatsugi S, Toya T, Ichiki C, Yatsugi SI, Koshiya K, Shimizu-Sasamata M, Yamaguchi T: Neuroprotective efficacy of YM872, an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats. J Pharmacol Exp Ther (1998) 287(2):559-566.
45. Lutsep H, Clark WM: Neuroprotection in acute ischaemic stroke. Current status and future potential. Drugs R&D (1999) 1(1):3-8.
46. Kawasaki-Yatsugi S, Takahashi M, Toya T, Ichiki C, Shimizu-Sasamata M, Yamaguchi T, Minematsu K: A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Res (1998) 793(1-2):39-46.
47. Haaberg A, Takahashi M, Yamaguchi T, Hjelstuen M, Haraldseth O: Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion. Brain Res (1998) 811(1-2):63-70.
48. Jain K: Neuroprotection in cerebrovascular disease. Expert Opin Investig Drugs (2000) 9(4):695-711.
49. Chimirri A, Gitto R, Zappala M: AMPA receptor antagonists. Exp Opin Ther Pat (1999) 9(5):557-570.
50. Schachter SC, Tarsy D: Remacemide: Current status and clinical applications. Expert Opin Investig Drugs (2000) 9(4):871-883.
51. Dyker AG, Lees KR: Remacemide hydrochloride: A double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke (1999) 30(9):1796-1801.
52. Capelli AM, Micheli F: CUK-315716/UK-240455 (Pfizer). Curr Opin Invest Drugs (2001) 2(12):1737-1739.
53. Auberson Y: Competitive AMPA antagonism: A novel mechanism for antiepileptic drugs? Drugs Future (2001) 26(5):463-471.
54. Nielsen E, Varming T, Mathiesen C, Jensen LH, Moller A, Gouliaev AH, Waetjen F, Drejer J: SPD 502: A water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. J Pharmacol Exp Ther (1999) 289(3):1492-1501.
55. Mueller A, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, George K, Kierstead A, Marriott TB, Moe ST, Newman MK et al. NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann NY Acad Sci (1999) 890:450-457.
56. Palmer G: Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets (2001) 2(3):241-271.
57. Verstraete M: Third-generation thrombolytic drugs. Am J Med (2000) 109(1):52-58.
58. Kimura K, Tsukahara K, Usui T, Okuda J, Kitamura Y, Kosuge M, Sano T, Tohyama S, Yamanaka O, Yoshii Y, Umemura S: Low-dose tissue plasminogen activator followed by planned rescue angioplasty reduces time to reperfusion for acute myocardial infarction treated at community hospitals. Jpn Circ J (2001) 65(10):901-906.
59. Seventh IBC International Symposium: Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs, Cambridge, Massachusetts, USA. IDdb Meeting Report (1996) October 21-23.
60. Schering AG: License Agreement on DSPA between Schering AG and Teijin. Press Release (1997) October 23.
61. British Biotech plc: British Biotech and BresaGen terminate E21R development agreement. Press Release (2002) July 23
62. Analyst report: UK Small Pharmaceuticals - British Biotech. ABN AMRO Bank NV USA (2000) September 29.
63. Delzoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M: Proact - A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke (1998) 29(1):4-11.
64. Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, Hacke W: Thrombolytic therapy for ischemic stroke - A review. Part II - Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Crit Care Med (2001) 29(9):1819-1825.
65. Osborn TM, LaMonte MP, Gaasch WR: Intravenous thrombolytic therapy for stroke: A review of recent studies and controversies. Ann Emerg Med (1999) 34(2):244-255.
66. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators: Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial. J Am Med Assoc (1998) 279(16):1265-1272.
67. Bogousslavsky J, Leclerc JR: Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke. Neurology (2001) 57(5 Suppl 2):S53-S57. An overview of GPIIb/IIIa blockade.
68. Coller BS: Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb Haemost (2001) 86(1):427-443.
69. Bogousslavsky J, Leclerc JR: Platelet glycoprotein IIb/IIIa blockade in acute ischemic stroke. Cerebrovasc Dis (2001) 11(4):287-293.
70. Weksler BB: Antiplatelet agents in stroke prevention - Combination therapy: Present and future. Cerebrovasc Dis (2000) 10(Suppl 5):41-48.
71. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet (1997) 349(9066):1641-1649.
72. The Abciximab in Ischemic Stroke Investigators: Abciximab in acute ischemic stroke - A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke (2000) 31(3):601-609.
73. Fuss C, Palmaz JC, Sprague EA: Fibrinogen: Structure, function, and surface interactions. J Vasc Interv Radiol (2001) 12(6):677-682.
74. Kamath S, Lip GYH: YM-337 (Yamanouchi). Curr Opin Investig Drugs (2001) 2(8):1093-1096.
75. Hirsch D, Yoles E, Belkin M, Schwartz M: Inflammation after axonal injury has conflicting consequences for recovery of function: Rescue of spared axons is impaired but regeneration is supported. J Neuroimmunol (1994) 50:9-16.
76. Guest A, Rao L, Olson M, Bunge R: BUNGE: The ability of human schwann cell grafts to promote regeneration in the transected nude rat spinal cord. Exp Neurol (1997) 148(2):502-522.
77. Lazarow-Spiegler O, Rapalino O, Agranov G, Schwartz M: Restricted inflammatory reaction in the CNS: A key impediment to axonal regeneration? Mol Med Today (1998) 4(8):337-342.
78. Dopp J, De Vellis J: Strategies or therapeutic manipulation of cytokines and their receptors in inflammatory neurodegenerative diseases. Mental Retard Dev Disability Res (1998) 4:200-211.
79. Jenkins W, Merzenich M: Reorganization of neocortical representations after brain injury: A neurophysiological model of the basis of recovery from stroke. Prog Brain Res (1987) 71:249-266.
80. Li Y, Jiang N, Powers C, Chopp M: Neuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1 immunoreactivity after focal cerebral ischemia in rats. Stroke (1998) 29(9):1972-1981.
81. Rijntjes M, Weiller C: Recovery of motor and language abilities after stroke: The contribution of functional imaging. Prog Neurobiol (2002) 66(2):109-122.
82. Johansson B, Grabowski M: Functional recovery after brain infarction: Plasticity and neural transplantation. Brain Pathol (1994) 4(1):85-95.
83. Kawamata T, Dietrich WD, Schallert T, Gotts JE, Cocke RR, Benowitz LI, Finklestein SP: Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci USA (1997) 94(15):8179-8184.
84. Chen R, Cohen LG, Hallett M: Nervous system reorganization following injury. Neuroscience (2002) 111(4):761-773. Recent article describing functional improvements and neuroplasticity following stroke.
85. Gladstone DJ, Black SE: Enhancing recovery after stroke with noradrenergic pharmacotherapy: A new frontier? Can J Neurol Sci (2000) 27(2):97-105.
86. Fisher M, Finklestein SP: Pharmacological approaches to stroke recovery. Cerebrovasc Dis (1999) 9(Suppl 5):29-32.
87. Ay H, Ay I, Koroshetz WJ, Finklestein SP: Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis (1999) 9(3):131-135.
88. Ay I, Sugmori H, Finklestein SP: Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats. Mol Brain Res (2001) 87(1):71-80.
89. Jiang N, Finklestein SP, Do T, Caday CG, Charette M, Chopp M: Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat. J Neurol Sci (1996) 139(2):173-179.
90. Sugimori H, Speller H, Finkelstein SP: Intravenous basic fibroblast growth factor produces a persistent reduction in infarct volume following permanent focal ischemia in rats. Neurosci Lett (2001) 300(1):13-16.
91. Kawamata T, Speliotes EK, Finklestein SP: The role of polypeptide growth factors in recovery from stroke. Adv Neurol (1997) 73:377-382.
92. Zhang L, Schallert T, Zhang ZG, Jiang Q, Arniego P, Li Q, Lu M, Chopp M: A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods (2002) 117(2):207-214. This article describes a sensitive neurobehavioral assessment of long-term sensorimotor dysfunction in preclinical animal models of stroke.
93. Iwai M, Abe K, Kitagawa H, Hayashi T: Gene therapy with adenovirus-mediated glial cell line-derived neurotrophic factor and neural stem cells activation after ischemic brain injury. Hum Cell (2001) 14(1):27-38.
94. Guan J, Miller OT, Waugh KM, McCarthy DC, Gluckman PD: Insulin-like growth factor-1 improves somatosensory function and reduces the extent of cortical infarction and ongoing neuronal loss after hypoxia-ischemia in rats. Neuroscience (2001) 105(2):299-306.
95. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST: CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology (2000) 39(5):777-787.
96. Abe K: Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab (2000) 20(10):1393-1408.
97. Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, Katakowski M, Zhang LJ, Lu M, Janakiraman N, Chopp M: Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery. Neurology (2002) 59(4):514-523.
98. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo JM, Chamorro A, Desmet A, Fiblast (trafermin) in acute stroke: Results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis (2002) 14(3-4):239-251.
99. Okano H: Neural stem cells: Progression of basic research and perspective for clinical application. Keio J Med (2002) 51(3):115-128.
100. Kruger GM, Morrison SJ: Brain repair by endogenous progenitors. Cell (2002) 110(4):399-402.
101. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H: Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke (1986) 17(3):472-476.
102. Hunter AJ, Mackay KB, Rogers DC: To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents. Trends Pharmacol Sci (1998) 19(2):59-66.
103. Davis SM, Albers GW, Diener HC, Lees KR, Norris J: Termination of acute stroke studies involving selfotel treatment. Lancet (1997) 349(9044):32.
104. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J: Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke (2000) 31(2):347-354.
105. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T: Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke (2000) 31(11):2543-2551.
106. Grotta JW, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L: Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke - Results of a phase IIa randomized trial. Stroke (1995) 26(4):602-605.
107. Lees KR: Cerestat and other NMDA antagonists in ischemic stroke. Neurology (1997) 49(5 Suppl 4):66-69.
108. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J: Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial. Lancet (2000) 355(9219):1949-1954.
109. Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF: Failure of the competitive N-methyl-D-aspartate antagonist selfotel (CGS 19755) in the treatment of severe head injury: Results of two phase III clinical trials. J Neurosurg (1999) 91(5):737-743.
110. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, Hansson L, Lacouciere Y, Muller J, Sleight P, Weber MA et al: Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial. Control Clin Trials (1998) 19(4):370-390.
111. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J et al: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. J Am Med Assoc (2003) 289(16):2128-2131.
112. Progress Collaborative Group: Randomised trial of a perindopril-based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet (2001) 358(9287):1033-1041.
113. Callahan A: Cerebrovascular disease and statins: A potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol (2001) 88(7B):33J-37J.
114. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, on behalf of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigtors: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. J Am Med Assoc (2001) 285(13):1711-1718.
115. COR Therapeutics Inc: COR Therapeutics' Cromafiban represents first once-a-day oral GPIIb-IIIa inhibitor in the clinic. Press Release (1999) March 08.
116. GlaxoSmithKline plc: Product development pipeline - October 2002. Company Publication (2002) October 23.
117. Aventis Pharma AG: Drug development pipeline: AVE-0545, VLA4 antagonists, AVE-4579, Factor Xa inhibitors, Insuman, LIT-976, AVE-7688, 1954, AVE-0547, 4011, IPL-512602. Company Communication (2002) July 12
118. BTG International Ltd: BGC 728 - A potent and effective agent for the treatment and prophylaxis of acute myocardial infarction and stroke. Company World Wide Web Site (2002) January 15.
119. Integra Life Sciences Corporation: Drug development pipeline: Integra. Company Communication (2001) June 09.
120. Bayer AG: Drug development pipeline: BAY-442041, IL-2 agonist, cGMP enhancer. Company Communication (2002) March 13.
121. Novogen Inc: Novogen achieves important effect on prostate tissue in the development of its anti-cancer drug, NV-06. Press Release (1999) June 15.
122. Novavax Inc: Novavax comments that E-selectin tolerogen treatment by NIH prevents strokes in animals. Press Release (2002) September 17.
123. Scarborough RM, Laibelman AM, Clizbe LA, Fretto LJ, Conley PB, Reynolds EE, Sedlock DM, Jantzen HM: Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y12). Bioorg Med Chem Lett (2001) 11(14):1805-1808.
124. Quan M, Pruitt J, Ellis C, Liauw A, Galemmo R Jr, Stouten P, Wityak J, Knabb R, Thoolen M, Wong P, Wexler R: Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett (1997) 7(21):2813-2818.
125. Quan ML, Ellis CD, He MY, Liauw AY, Woerner FJ, Alexander RS, Knabb RM, Lam PYS, Luettgen JM, Wong PC, Wright MR, Wexler RR: Nonbenzamidine tetrazole derivatives as Factor Xa inhibitors. Bioorg Med Chem Lett (2003) 13(3);369-373.
126. Bayer AG: Building Bayer healthcare: 2001 & beyond. Company Presentation (2002) March 15.
127. PAION GmBH: Company profile. Company World Wide Web Site (2002) March 05.
128. D Pharm Ltd: D-Pharm announces encouraging results for DP-b99 in its first phase II stroke study. Press Release (2003) March 11.
129. Ono Pharmaceutical Co Ltd: Annual flash report (unaudited): Year ended March 31 2002. Company Publication (2002) May 17
130. GlaxoSmithKline plc: Product development pipeline: October 2001. Company Publication (2001) October 23
131. Yamanouchi wants to make Lipitor no 1 statin in Japan. Pharma Jpn (2001) 1741:3-5.
132. Protein Design Labs Inc: Yamanouchi/PDL anti-platelet antibody inhibits platelet coagulation with little increase in bleeding. Press Release (1995) November 29
133. Koyama M, Inoue T, Ogino R, Saito K, Ohno T: Effects of SUN N4057 a novel neuroprotectant, on cerebral infarction induced by thrombotic middle cerebral artery occlusion in rats. Jpn J Pharmacol (1997) 79(Suppl 1):P440.
134. Neurochem Inc: Neurochem announces positive progress for its clinical program on hemorrhagic stroke due to cerebral amyloid angiopathy. Press Release (2002) October 25
135. Neuron Therapeutics Inc: Neuron Therapeutics announces first patient in investigational study of novel stroke therapy. Press Release (2001) January 29.
136. Millennium Pharmaceuticals Ltd: Millennium Pharmaceuticals: 22nd Annual Healthcare Conference. Company Presentation (2001) June 12.
137. Bayer AG: Drug development pipeline: New projects in development at Bayer. Company Communication (2001) February 01.
138. Sugimura M, Nakayama W, Sato T, Shirasaki Y: Effect of DY-9760, novel calmodulin antagonist, on calcium induced cell death in NIE-115 neuroblastoma cells. J Cereb Blood Flow Metab (1995) S434.
139. University of Pittsburgh: University of Pittsburgh to begin second phase of cell implant study for stroke patients; Results of groundbreaking initial study were encouraging. Press Release (2001) March 15
140. Saegis Pharmaceuticals Inc: Saegis Pharmaceuticals broadens research collaboration with Johns Hopkins University. Press Release (2002) November 19.
141. Viacell Inc: ViaCell obtains exclusive worldwide license to novel protein for use in treatment of stroke recovery and other neurological and neuromuscular disorders. Press Release (2002) August 14.
142. Axaron Bioscience AG: Drug candidates. Company World Wide Web Site (2003) April 16.
143. Adekale M: Cancer Gene Therapy - 11th International Conference, London, UK. IDdb Meeting Report (2002) July 11-12.
144. Idun Pharmaceuticals. Idun licenses bcl-2 gene to Selective Genetics for gene therapy applications: Anti-apoptosis gene to combat tissue injury. Press Release (2001) February 27.
145. ReNeuron Ltd: ReNeuron Holdings plc AGM statement and update on cell stability. Press Release (2001) September 11.
146. Boston Life Sciences Inc: Boston Life Sciences completes acquisition of central nervous system growth factor - Major benefit potential in treatment of stroke and spinal cord injury. Press Release (1995) July 25.
147. ThromboGenics Ltd. Pipeline product V: PIGF. Company World Wide Web Site (2003) July 08.